DDInter1238 DDInter1147
Mogamulizumab is a humanized monoclonal antibody (mAb) directed against CC chemokine receptor 4 (CCR4) for the treatment of Mycosis Fungoides (MF) and Sézary Syndrome (SS), the most common subtypes of cutaneous T-cell lymphoma. Cutaneous T-cell lymphomas occur when certain white blood cells, called T cells, become cancerous; these cancers typically affect the skin, causing various types of skin lesions. On August 8 2018, the U.S. Food and Drug Administration (FDA) approved mogamulizumab injection (also known as _Poteligeo_) for intravenous use for the treatment of adult patients with relapsed or refractory mycosis fungoides (MF) or Sézary syndrome (SS) after at least one prior systemic therapy. It was approved for the same indications in Canada in June 2022. Mogamuliz
Meningococcal group C polysaccharide is group-specific polysaccharide antigens extracted and purified from *Neisseria meningitidis* serogroup C. *N. meningitidis* is a bacteria that causes endemic and epidemic diseases including meningitis and meningococcemia. It is subcutaneously administered as an active immunization against the invasive meningococcal disease caused by the serogroup C.
Mogamulizumab {u} may cause a minor interaction that can limit clinical effects when taken with {v} Vitamin E
Mogamulizumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Canakinumab
Mogamulizumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Vibrio cholerae CVD 103-HgR strain live antigen
Mogamulizumab {u} may lead to a major life threatening interaction when taken with {v} Upadacitinib
Mogamulizumab {u} may lead to a major life threatening interaction when taken with {v} Cladribine
Mogamulizumab may cause a minor interaction that can limit clinical effects when taken with Vitamin E
Mogamulizumab may cause a moderate interaction that could exacerbate diseases when taken with Canakinumab
Mogamulizumab may cause a moderate interaction that could exacerbate diseases when taken with Vibrio cholerae CVD 103-HgR strain live antigen
Mogamulizumab may lead to a major life threatening interaction when taken with Upadacitinib
Mogamulizumab may lead to a major life threatening interaction when taken with Cladribine